2023 is a New Year, Kangyuxin Biotechnology Co., Ltd. has also embarked on a new journey. At the end of 2022, Kangyuxin Biology received good news - according to the relevant provisions of the national "High-tech Enterprise identification Management Measures" and "High-tech enterprise identification Management Guidelines", relying on professional R & D team, strong technical strength, continuous innovation ability, scientific enterprise management, Kangyuxin Biotechnology Co., Ltd. was successfully identified as a national high-tech enterprise.

       On March 10, Baiyin High-tech Zone held a high-quality development conference and strong science and technology, strong industrial action commendation conference. Liu Changfa, deputy mayor of the Municipal government and first secretary of the Party Working Committee of Baiyin High-tech Zone, attended the meeting and made a speech, and Zhou Dong, secretary of the Party Working Committee and director of the Management Committee of the High-Tech Zone, presided over the meeting. At the meeting, Zhongkang Yuxin Biotechnology Co., Ltd. was commended as a new high-tech enterprise and a new regulation enterprise, and Mr. Wang Linshan, vice president of the company, spoke as a representative of the enterprise.

        Recently, the company has also received a "high-tech enterprise" certification, which officially entered the ranks of national high-tech enterprises. Start a new chapter.

National high-tech enterprises, also known as state-level high-tech enterprises, are special qualifications established by the state to support and encourage the development of high-tech enterprises, adjust industrial structure and enhance national economic competitiveness, and occupy a very important strategic position in China's economic development. The successful selection of our company is a full affirmation of our innovation ability, technical ability, management level and service level by the industry and society, and the best praise for the technical achievements of all our employees and the work of Shinle.

The recognition of high-tech enterprises is the recognition and affirmation of the company by the state, and it is an indispensable hard sign for enterprises that rely on science and technology, and has a significant influence on the development of enterprises. The identification of high-tech enterprises is the fundamental driving force for the development of enterprises, and the identification policy of high-tech enterprises is a guiding policy, which aims to guide enterprises to adjust the industrial results, take the development path of independent innovation and continuous innovation, stimulate the enthusiasm of independent innovation of enterprises, and improve the ability of scientific and technological innovation.

The evaluation as a national high-tech enterprise is a great encouragement to all our employees, but also put forward higher requirements for the follow-up development of our company, our company will further promote the company's independent innovation, independent research and development process, but also another milestone in the development history of the company. In the future, our company will continue to train high-quality talent team to provide follow-up impetus for independent innovation; Pay more attention to independent innovation, protect intellectual property rights, and enhance the core competitiveness of enterprises; Continue to increase investment in scientific research, enrich the vitality of enterprise innovation and development, so as to further enhance the core competitiveness of the enterprise market and create brilliance.

Kohn & Shawn Pharmatech

       Kangyuxin Biotechnology Co., Ltd. was established in October 2013, specializing in the research and development, production, sales and related service technology development of pyrazine intermediates and process libraries. Kangyuxin has more than 2,000 square meters of standardized laboratories, with an output value of more than 80 million yuan in 2022. The core technology of pyrazine derivatives of Kangyuxin ranks the leading level in China, and the varieties and orders of pyrazine series products are ranked first in the domestic industry. Kangyuxin has an experienced and high-quality drug process research and development team, which can realize the research and development and process production from lead compounds to clinical batch apis. Kangyuxin Drug Quality research team can provide effective data and method validation for drug registration and research.

      The company was supported by the innovation Fund of Gansu Province in 2016, and was identified as the first batch of provincial science and technology innovation enterprises by the Department of Science and Technology of Gansu Province, and has been supported by the science and technology innovation Fund of Lanzhou and Baiyin for many times. Wang Youwei, the founder of the company, was named "One hundred innovative and entrepreneurial models in Lanzhou City" in 2015. Kangyuxin, as the first domestic enterprise to develop a broad spectrum antiviral new drug "Fapiravir", was shortlisted in the eighth batch of key protection enterprises for epidemic prevention materials in Gansu Province. Kangyuxin won the Excellence Award of the 10th China Innovation and Entrepreneurship Competition National Biomedical Industry Competition in 2021 (the second place in the group), and the second place in the Gansu Division of the 10th China Innovation and Entrepreneurship Competition. Won the first prize in the Northwest region of the 2020 "Guotong Cup" Lanzhou University Global Alumni Entrepreneurship Competition, and the first prize of the Baiyin Double Innovation Competition for two consecutive years in 2020 and 2021. In 2022, it will be evaluated as a high-tech enterprise and a specialized and special new enterprise.